Locally Advanced Colorectal Carcinoma Incurable | Colorectal cancer metastatic incurable | Adenocarcinoma | Mucinous Adenocarcinoma | Carcinoma, Signet Ring Cell | Colorectal Undifferentiated Carcinoma | Neuroendocrine Carcinoma Excluded
Item
histologic diagnosis of locally advanced or metastatic crc that is not curable. the histology types to be included are adenocarcinoma, mucinous adenocarcinoma, signet ring, and undifferentiated. patients with neuroendocrine carcinomas will be excluded.
boolean
C0009402 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C0175969 (UMLS CUI [1,4])
C0948380 (UMLS CUI [2,1])
C0175969 (UMLS CUI [2,2])
C0001418 (UMLS CUI [3])
C0007130 (UMLS CUI [4])
C0206696 (UMLS CUI [5])
C1707443 (UMLS CUI [6])
C0206695 (UMLS CUI [7,1])
C2828389 (UMLS CUI [7,2])
First line treatment Cycle Quantity | FOLFOX Regimen | FOLFIRI Regimen | Bevacizumab | Colorectal cancer metastatic | Colorectal cancer recurrent | Adjuvant therapy Completed
Item
received 6 cycles (3 months [12 weeks]) of first-line therapy with folfox or folfiri, plus bevacizumab for metastatic crc. patients have received at least 5 cycles with bevacizumab. patients who received 6 cycles of first-line therapy with folfox or folfiri, plus bevacizumab for recurrent crc that has relapsed at least 12 months after completion of adjuvant therapy will also be included. all standard folfox ( or folfiri) regimens given on a biweekly schedule will be permitted; however, 21-day regimens will not be allowed.
boolean
C1708063 (UMLS CUI [1,1])
C1302181 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0392943 (UMLS CUI [2])
C1880658 (UMLS CUI [3])
C0796392 (UMLS CUI [4])
C0948380 (UMLS CUI [5])
C0854750 (UMLS CUI [6])
C0677850 (UMLS CUI [7,1])
C0205197 (UMLS CUI [7,2])
First line treatment Elapsed Time Randomization
Item
no more than 4 weeks may pass between the end of first-line therapy (that is, day 14 of cycle 6) and randomization.
boolean
C1708063 (UMLS CUI [1,1])
C2826303 (UMLS CUI [1,2])
C0034656 (UMLS CUI [1,3])
In complete remission CT scan | Partial response CT scan | Stable Disease CT scan | In complete remission MRI | Partial response MRI | Stable Disease MRI
Item
documented evidence of tumor response of cr, pr, or sd by computed tomography (ct) scan or magnetic resonance imaging (mri). confirmation of response is not required.
boolean
C0677874 (UMLS CUI [1,1])
C0040405 (UMLS CUI [1,2])
C1521726 (UMLS CUI [2,1])
C0040405 (UMLS CUI [2,2])
C0677946 (UMLS CUI [3,1])
C0040405 (UMLS CUI [3,2])
C0677874 (UMLS CUI [4,1])
C0024485 (UMLS CUI [4,2])
C1521726 (UMLS CUI [5,1])
C0024485 (UMLS CUI [5,2])
C0677946 (UMLS CUI [6,1])
C0024485 (UMLS CUI [6,2])
Lacking Able to swallow Tablets
Item
are unable to swallow tablets.
boolean
C0332268 (UMLS CUI [1,1])
C2712086 (UMLS CUI [1,2])
C0039225 (UMLS CUI [1,3])
Drugs, Non-Prescription
Item
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C0013231 (UMLS CUI [1])
CNS metastases
Item
have known central nervous system metastases.
boolean
C0686377 (UMLS CUI [1])
Cancer treatment
Item
are receiving concurrent administration of any other antitumor therapy.
boolean
C0920425 (UMLS CUI [1])
Heart Disease | Liver disease | Kidney Disease | Mental disorders | Communicable Disease
Item
patients who have significant heart, liver, kidney, or psychiatric disease or have an active infection
boolean
C0018799 (UMLS CUI [1])
C0023895 (UMLS CUI [2])
C0022658 (UMLS CUI [3])
C0004936 (UMLS CUI [4])
C0009450 (UMLS CUI [5])